Is allergen immunotherapy a model of personalized treatment in pediatric respiratory allergy?
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
13 Feb 2024
13 Feb 2024
Historique:
medline:
15
2
2024
pubmed:
15
2
2024
entrez:
15
2
2024
Statut:
aheadofprint
Résumé
To review recent evidence on allergen immunotherapy (AIT) as a model of personalized medicine in the treatment of children and adolescents with respiratory allergies. Meta-analysis and systematic review studies continue to point out that AIT is an effective treatment for children with respiratory allergies. Molecular allergy allows the understanding of patient sensitization profiles that frequently change the prescription of AIT. There is still a lack of evidence showing that this personalized prescription of AIT is associated with better clinical outcomes. The nasal allergen challenge has extended the indications of AIT for a new group of subjects with local allergic rhinitis. Patient selection of allergens involved in the increasingly personalized composition of extracts to be used in AIT increasingly characterizes it as personalized medicine. Despite the numerous studies carried out to identify the best biomarker to evaluate the response to AIT, there is still much disagreement, and clinical assessment (symptoms, quality of life, among others) continues to be the best way to evaluate the therapeutic success of AIT.
Identifiants
pubmed: 38359080
doi: 10.1097/ACI.0000000000000968
pii: 00130832-990000000-00109
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Durham S, Shamji M. Allergen immunotherapy: past, present and future. Nat Rev Immunol 2023; 23:317–328.
Incorvaia C, Al-Ahmad M, Ansotegui I, et al. Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. Allergy 2021; 76:1041–1052.
Rodríguez-Domínguez A, Berings M, Rohrbach A, et al. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy. J Allergy Clin Immunol 2020; 146:1097–1108.
Stringari G, Tripodi S, Caffarelli C, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol 2014; 134:75–81.
Camacho G, Arjona A, Fernández-Cantalejo J, Catalán J. How molecular diagnosis may modify immunotherapy prescription in multisensitized pollen-allergic children. Allergol Immunopathol (Madr) 2018; 46:552–556.
Burgos A, Torres-Borrego J, Terán A, et al. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen. Pediatr Allergy Immunol 2018; 29:369–374.
Forchert L, Potapova E, Panetta V, et al. Der p 23-specific IgE response throughout childhood and its association with allergic disease: a birth cohort study. Pediatric Allergy Immunol 2022; 33:e13829.
Chen K, Zieglmayer P, Zieglmayer R, et al. Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotheraphy. J Allergy Clin Immunol 2019; 143:1248–1252.
Potapova E, Bordas-Le Floch V, Schlederer T, et al. Molecular reactivity profilling upon immunotheraphy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. Allergy 2022; 77:3084–3095.
Rondón C, Campo P, Salas M, et al. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial. Allergy 2016; 71:1057–1061.
Rondón C, Blanca-López N, Campo P, et al. Specific immunotherapy in local allergic rhinitis: a randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy 2018; 73:905–915.
Bozek A, Kolodziejczgk K, Jarzab J. Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis. Ann Asthma Allergy Immunol 2018; 120:53–58.
Canonica GW, Bachert C, Hellings P, et al. Allergen immunotherapy (AIT): a prototype of precision medicine. World Allergy Organ J 2015; 8:31.
Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol 2020; 25: (Suppl 25): 1–101.
Aarestrup FM, Taketomi EA, Santos Galvão CE, et al. Good clinical practice recommendations in allergen immunotherapy: position paper of the Brazilian Association of Allergy and Immunology – ASBAI. World Allergy Organ J 2022; 15:100697.
Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014; 7:6.
Aarestrup FM, Lira GVAG, Taketomi EA, et al. Brazilian guidelines for allergen immunotherapy in the treatment of allergic rhinitis. Rev Assoc Med Bras 2023; 69:e2023D695.
Pajno GB, Bernardini R, Peroni D, et al. Allergen-specific immunotherapy panel of the Italian Society of Pediatric Allergy and Immunology (SIAIP). Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr 2017; 43:13.
Calderon MA, Casale TB, Nelson HS, et al. Extrapolating evidence-based medicine of AIT into clinical practice in the United States. J Allergy Clin Immunol Pract 2023; 11:1100–1115.
Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127: (Suppl): S1–55.
Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91:709–722.
Calderon MA, Larenas D, Kleine-Tebbe J, et al. European Academy of Allergy and Clinical Immunology task force report on dose-response relationship in allergen-specific immunotherapy. Allergy 2011; 66:1345–1359.
Nelson HS. Standardized allergen extracts for allergen immunotherapy. Allergy Asthma Proc 2022; 43:327–332.
Nelson HS. How important is proper dosing for subcutaneous and sublingual allergy immunotherapy? Allergy Asthma Proc 2021; 42:368–377.
Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011; 66:740–752.
Arasi S, Corsello G, Villani A, Pajno GB. The future outlook on allergen immunotherapy in children: 2018 and beyond. Ital J Pediatr 2018; 44:80.
Petersen KD, Kronborg C, Larsen JN, et al. Patient related outcomes in a real life prospective follow up study: allergen immunotherapy increase quality of life and reduce sick days. World Allergy Organ J 2013; 6:15.
Aarestrup MF, Aarestrup PF, de Andrade MS, et al. Satisfaction of allergic patients treated with house dust mite sublingual immunotherapy. Int J Immunopathol Pharmacol 2021; 35:20587384211015528.
Aj JA, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89–95.
Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol 2013; 9:267–276.
Matricardi PM, Potapova E, Forchert L, et al. Biomarkers for allergen immunotherapy: antibody responses and digital health systems. Pediatr Allergy Immunol 2020; 31 (sup 25):18–28.
Sahiner UM, Giovanni M, Escribese MM, et al. Mechanisms of allergen immunotherapy and potential biomarkers for clinical evaluation. J Pers Med 2023; 13:845.
Layhadi JA, Lalioti A, Palmer E, et al. Mechanisms and predictive biomarkers of allergen immunotherapy in the clinic. J Allegy Clin Immunol Pract 2023; 12:59–66.
Zemelka-Wiacek M, Agache I, Adkis CA, et al. Hot topics in allergen immunotherapy, 2023: Current status and future perspective. Allergy 2023; doi: 10.1111/all.15945. [Online ahead of print].
doi: 10.1111/all.15945.
Pitsios C. Allergen immunotherapy: biomarkers and clinical outcome measures. J Asthma Allergy 2021; 14:141–148.
Shamji MH, Layhadi JA, Scadding GW, et al. Basophil expression of diamine oxidases: a novel biomarker of allergen immunotherapy response. J Allergy Clin Immunol 2015; 133:913–921.